Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : PM012
Therapeutic Area : Neurology
Study Phase : Phase II/ Phase III
Sponsor : Vision Sensing Acquisition Corp
Deal Size : Undisclosed
Deal Type : Merger
Vision Sensing Announces Merger with Mediforum Co., Ltd
Details : The combined company will advance Mediforum's drugs, PM012 for Alzheimer’s Disease and MF018 for chemotherapy-induced peripheral neuropathy, currently in Phase 2b trials.
Product Name : PM012
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 16, 2024
Lead Product(s) : PM012
Therapeutic Area : Neurology
Highest Development Status : Phase II/ Phase III
Sponsor : Vision Sensing Acquisition Corp
Deal Size : Undisclosed
Deal Type : Merger